Prognostic test to predict metastasis in clear cell kidney cancer
Official title: A PROGNOSTIC ASSAY FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Funded at Lagrange Scientific, LLC · NIH-11412572 · Data updated 2026-11-12
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lagrange Scientific, LLC NIH-funded |
| Lab location | 1 site (Pewee Valley, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $582,245 |
| NIH project number | 5R44CA288032-03 |
| Project ID | NIH-11412572 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with clear cell renal cell carcinoma whose tumors are available for biomarker testing.
✕Less likely to help
Patients without aggressive biomarker signatures or those unable to undergo tissue testing may see no direct benefit.
What this research studies
This project aims to develop a protein/metabolite-based panel from tumor tissue that can forecast early metastatic spread in clear cell renal cell carcinoma. It uses a Phase II SBIR approach to identify and validate a 12-marker set that indicates aggressive cancer subtypes. The goal is to help clinicians tailor treatment timing, potentially starting systemic therapy earlier for high-risk patients or avoiding overtreatment for those unlikely to metastasize. The work involves translating laboratory findings into a clinically usable assay that can guide decisions in real-world care.
Why it matters
Potential benefit: If successful, patients with high-risk tumors could receive timely therapy to prevent metastasis, while low-risk patients might avoid unnecessary treatment.
How similar studies have gone: Prior biomarker panels have shown promise in predicting progression in some cancers, but this specific 12-marker panel for ccRCC is novel and requires validation.
Where this research is happening
-
Lagrange Scientific, LLC
Pewee Valley, United States Active
Researchers
- Principal investigator: Coughlin, Richard Thomas — Lagrange Scientific, LLC
- Study coordinator: Coughlin, Richard Thomas
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
-
How mitochondrial activity and cancer spread are affected by tRNA changes in kidney cancer
This project looks at how specific tRNA modifications influence mitochondrial function and the spread of kidney cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.